These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 23196204

  • 1. Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccine.
    Sharma H, Yadav S, Lalwani S, Kapre S, Jadhav S, Parekh S, Palkar S, Ravetkar S, Bahl S, Kumar R, Shewale S.
    Vaccine; 2013 Jan 07; 31(3):444-7. PubMed ID: 23196204
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children.
    Sharma HJ, Yadav S, Lalwani SK, Kapre SV, Jadhav SS, Chakravarty A, Parekh SS, Palkar S, Bhardwaj SH, Namjoshi GS, Verma V.
    Hum Vaccin; 2011 Apr 07; 7(4):451-7. PubMed ID: 21403463
    [Abstract] [Full Text] [Related]

  • 3. DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old.
    Gunardi H, Rusmil K, Fadlyana E, Soedjatmiko, Dhamayanti M, Sekartini R, Tarigan R, Satari HI, Medise BE, Sari RM, Bachtiar NS, Kartasasmita CB, Hadinegoro SRS.
    BMC Pediatr; 2018 May 28; 18(1):177. PubMed ID: 29804542
    [Abstract] [Full Text] [Related]

  • 4. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH, Thein SA, Aye A, Han HH, Bock HL, David MP, Schuerman L.
    Pediatr Infect Dis J; 2006 Aug 28; 25(8):706-12. PubMed ID: 16874170
    [Abstract] [Full Text] [Related]

  • 5. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U, DTP-HBV-IPV-059 Study Group, DTP-HBV-IPV-096 Study Group, Sänger R, Jacquet JM, Schuerman L.
    Vaccine; 2007 Jan 22; 25(6):1055-63. PubMed ID: 17049692
    [Abstract] [Full Text] [Related]

  • 6. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine.
    Faingezicht I, Avila-Aguerro ML, Cervantes Y, Fourneau M, Clemens SA.
    Rev Panam Salud Publica; 2002 Oct 22; 12(4):247-57. PubMed ID: 12431356
    [Abstract] [Full Text] [Related]

  • 7. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
    Nolan T, Altmann A, Skeljo M, Streeton C, Schuerman L.
    Vaccine; 2004 Nov 15; 23(1):14-20. PubMed ID: 15519702
    [Abstract] [Full Text] [Related]

  • 8. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
    Szenborn L, Czajka H, Brzostek J, Konior R, Caubet M, Ulianov L, Leyssen M.
    Pediatr Infect Dis J; 2013 Jul 15; 32(7):777-85. PubMed ID: 23838777
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK, Rajadurai VS, Amin Z, Sriram B, Yee MF, Han HH, Bock HL, Safary A.
    Southeast Asian J Trop Med Public Health; 2004 Sep 15; 35(3):685-92. PubMed ID: 15689088
    [Abstract] [Full Text] [Related]

  • 10. Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants.
    Gandhi DJ, Dhaded SM, Ravi MD, Dubey AP, Kundu R, Lalwani SK, Chhatwal J, Mathew LG, Gupta M, Sharma SD, Bavdekar SB, Jayanth MV, Ravinuthala S, Sil A, Dhingra MS.
    Hum Vaccin Immunother; 2016 Apr 02; 12(4):946-54. PubMed ID: 26580093
    [Abstract] [Full Text] [Related]

  • 11. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, Dobbelaere K, Boutriau D.
    Int J Infect Dis; 2008 May 02; 12(3):278-88. PubMed ID: 17981067
    [Abstract] [Full Text] [Related]

  • 12. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.
    Marshall H, McIntyre P, Roberton D, Dinan L, Hardt K.
    Int J Infect Dis; 2010 Jan 02; 14(1):e41-9. PubMed ID: 19467896
    [Abstract] [Full Text] [Related]

  • 13. Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine manufactured using small and large scale manufacturing process.
    Sharma HJ, Patil VD, Lalwani SK, Manglani MV, Ravichandran L, Kapre SV, Jadhav SS, Parekh SS, Ashtagi G, Malshe N, Palkar S, Wade M, Arunprasath TK, Kumar D, Shewale SD.
    Vaccine; 2012 Jan 11; 30(3):510-6. PubMed ID: 22119927
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C, Belohradsky BH, Stojanov S, Bonnet E, Petersen G, Liese JG.
    Vaccine; 2008 Jun 13; 26(25):3142-52. PubMed ID: 18502545
    [Abstract] [Full Text] [Related]

  • 15. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting.
    Lim FS, Phua KB, Lee BW, Quak SH, Teoh YL, Ramakrishnan G, Han HH, Van Der Meeren O, Jacquets JM, Bock HL.
    Southeast Asian J Trop Med Public Health; 2011 Jan 13; 42(1):138-47. PubMed ID: 21323176
    [Abstract] [Full Text] [Related]

  • 16. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia.
    Wong SL, Soosai P, Teoh YL, Han HH, Lefevre I, Bock HL.
    Southeast Asian J Trop Med Public Health; 2008 May 13; 39(3):474-83. PubMed ID: 18564687
    [Abstract] [Full Text] [Related]

  • 17. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children.
    Pancharoen C, Chotpitayasunondh T, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2012 May 13; 43(3):687-98. PubMed ID: 23077849
    [Abstract] [Full Text] [Related]

  • 18. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.
    Gatchalian S, Reyes M, Bermal N, Chandrasekaran V, Han HH, Bock HL, Lefevre I.
    Hum Vaccin; 2008 May 13; 4(1):60-6. PubMed ID: 18376148
    [Abstract] [Full Text] [Related]

  • 19. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Chen CJ, Chavand P, Ortiz E.
    Int J Infect Dis; 2007 Nov 13; 11(6):488-95. PubMed ID: 17349809
    [Abstract] [Full Text] [Related]

  • 20. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M, Zambrano B, Santos-Lima E.
    Pediatr Infect Dis J; 2012 Jan 13; 31(1):e24-30. PubMed ID: 22157567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.